BRPI0813763A2 - Inibidores da protease de cisteína - Google Patents

Inibidores da protease de cisteína

Info

Publication number
BRPI0813763A2
BRPI0813763A2 BRPI0813763-3A2A BRPI0813763A BRPI0813763A2 BR PI0813763 A2 BRPI0813763 A2 BR PI0813763A2 BR PI0813763 A BRPI0813763 A BR PI0813763A BR PI0813763 A2 BRPI0813763 A2 BR PI0813763A2
Authority
BR
Brazil
Prior art keywords
protease inhibitors
cystein protease
cystein
inhibitors
protease
Prior art date
Application number
BRPI0813763-3A2A
Other languages
English (en)
Inventor
Magnus Nilsson
Lourdes Oden
Pia Kahnberg
Urszula Grabowska
Original Assignee
Medivir Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medivir Ab filed Critical Medivir Ab
Publication of BRPI0813763A2 publication Critical patent/BRPI0813763A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BRPI0813763-3A2A 2007-06-27 2008-06-26 Inibidores da protease de cisteína BRPI0813763A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US92943707P 2007-06-27 2007-06-27
EP07123771 2007-12-20
PCT/EP2008/058136 WO2009000877A1 (en) 2007-06-27 2008-06-26 Cysteine protease inhibitors

Publications (1)

Publication Number Publication Date
BRPI0813763A2 true BRPI0813763A2 (pt) 2014-12-30

Family

ID=40020008

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0813763-3A2A BRPI0813763A2 (pt) 2007-06-27 2008-06-26 Inibidores da protease de cisteína

Country Status (18)

Country Link
US (3) US7893067B2 (pt)
EP (1) EP2167507B1 (pt)
JP (1) JP5501961B2 (pt)
KR (1) KR101552150B1 (pt)
CN (1) CN101687880B (pt)
AR (1) AR067363A1 (pt)
AU (1) AU2008267166B2 (pt)
BR (1) BRPI0813763A2 (pt)
CA (1) CA2690344C (pt)
DK (1) DK2167507T3 (pt)
EA (1) EA017395B1 (pt)
ES (1) ES2573229T3 (pt)
MX (1) MX2009013789A (pt)
MY (1) MY149191A (pt)
PL (1) PL2167507T3 (pt)
TW (1) TWI419893B (pt)
WO (1) WO2009000877A1 (pt)
ZA (1) ZA200908771B (pt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7893067B2 (en) 2007-06-27 2011-02-22 Medivir Ab Cysteine protease inhibitors
GB0817424D0 (en) 2008-09-24 2008-10-29 Medivir Ab Protease inhibitors
WO2010137944A1 (en) * 2009-05-27 2010-12-02 N.V. Nutricia Treatment of hypercalcaemia

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR013079A1 (es) 1997-05-06 2000-12-13 Smithkline Beecham Corp Derivados sustituidos de tetrahidrofurano-3-onas, de tetrahidropirano-3- onas y tetrahidrotiofen-3-onas, un procedimiento para su preparacion unacomposicion farmaceutica de un medicamento util como inhibidores de proteasas e intermediarios
GB0003111D0 (en) 2000-02-10 2000-03-29 Novartis Ag Organic compounds
EP1358183B1 (en) 2000-11-17 2006-04-12 Medivir Ab Cysteine protease inhibitors
PT1362052E (pt) 2001-01-17 2007-04-30 Amura Therapeutics Ltd Inibidores de cruzipaína e de outras proteases de cisteína
CA2548600A1 (en) 2003-12-12 2005-06-23 Merck Frosst Canada & Co. Cathepsin cysteine protease inhibitors
US20080200975A1 (en) 2004-01-06 2008-08-21 Nicast Ltd. Vascular Prosthesis with Anastomotic Member
DE602005019971D1 (de) * 2004-01-08 2010-04-29 Medivir Ab Inhibitoren von cysteinprotease
EP1706402A4 (en) 2004-01-08 2009-03-18 Merck Frosst Canada Ltd CATHEPSINCYSTEINPROTEASEHEMMER
GB0513839D0 (en) 2005-07-07 2005-08-10 Medivir Ab Cysteine protease inhibitors
GB0614052D0 (en) 2006-07-14 2006-08-23 Amura Therapeutics Ltd Compounds
US7893067B2 (en) * 2007-06-27 2011-02-22 Medivir Ab Cysteine protease inhibitors
GB0804702D0 (en) * 2008-03-13 2008-04-16 Amura Therapeutics Ltd Compounds

Also Published As

Publication number Publication date
MX2009013789A (es) 2010-02-01
MY149191A (en) 2013-07-31
DK2167507T3 (en) 2016-06-13
EA017395B1 (ru) 2012-12-28
US7893067B2 (en) 2011-02-22
PL2167507T3 (pl) 2016-09-30
CA2690344A1 (en) 2008-12-31
JP2010531336A (ja) 2010-09-24
KR101552150B1 (ko) 2015-09-10
AU2008267166A1 (en) 2008-12-31
US20120220602A1 (en) 2012-08-30
EA201070062A1 (ru) 2010-08-30
JP5501961B2 (ja) 2014-05-28
US8466158B2 (en) 2013-06-18
CN101687880B (zh) 2012-09-05
US20090023748A1 (en) 2009-01-22
CN101687880A (zh) 2010-03-31
US8198283B2 (en) 2012-06-12
TW200911818A (en) 2009-03-16
ZA200908771B (en) 2011-04-28
US20110105524A1 (en) 2011-05-05
AU2008267166B2 (en) 2011-04-21
ES2573229T3 (es) 2016-06-06
TWI419893B (zh) 2013-12-21
EP2167507B1 (en) 2016-03-02
WO2009000877A1 (en) 2008-12-31
KR20100040879A (ko) 2010-04-21
CA2690344C (en) 2015-06-02
HK1140480A1 (en) 2010-10-15
EP2167507A1 (en) 2010-03-31
AR067363A1 (es) 2009-10-07

Similar Documents

Publication Publication Date Title
LTPA2017010I1 (lt) Proteazomos inhibitoriai
BRPI0807547A2 (pt) Inibidores de aspartil protease hetercíclicos
CR10831A (es) INHIBIDORES ESPIRO CETONA DE ACETIL-CoA CARBOXILASA
DK2041138T3 (da) Pyrroltriazinkinase-inhibitorer
DK2024375T3 (da) Cyclopropyl-kondenserede indolobenzazepin-HCV-NS5B-hæmmere
NO20082895L (no) Hoytrykks-hoyspenningspenetratorsammensetning
EP2305306A4 (en) NEURO INVASION INHIBITOR
BRPI0818800A2 (pt) Protease de streptomyces
BRPI1011267A2 (pt) inibidores de protease
DK2066662T3 (da) Serinhydrolaseinhibitorer
DK2131969T3 (da) Højtryksrenser
DE602008003159D1 (de) Schalter
BRPI0922283A2 (pt) inibidores da cistéina protease
BRPI0918966A2 (pt) inibidores de protease
IT1395847B1 (it) Complesso di interruttore di pressione
ATE522533T1 (de) Pyrazolopyrimidinonkinaseinhibitor
NO20070960A (no) Teine
DE602007009087D1 (de) Zerebraler vasospasmus-inhibitor
BRPI0715729A2 (pt) inibidores para glyt-1
BRPI0919073A2 (pt) inibidores de protease
FI20065032A0 (fi) Menetelmä asbestialtistumiseen liittyvien keuhkosyöpien tunnistamiseksi
EP2168954A4 (en) cysteine protease inhibitor
FIU20060267U0 (fi) Hissijärjestelmä
ES1062650Y (es) Sacapuntas con deposito
ITRO20060005U1 (it) Minipallet 1a

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notice of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06I Publication of requirement cancelled [chapter 6.9 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 6.6.1 NA RPI NO 2467 DE 17/04/2018 POR TER SIDO INDEVIDA.

B07A Technical examination (opinion): publication of technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL